MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 249 filers reported holding MIRATI THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.44 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,565,957 | +24.2% | 242,561 | +3.0% | 0.01% | +40.0% |
| Q2 2023 | $8,509,663 | -4.2% | 235,529 | -1.4% | 0.01% | 0.0% |
| Q1 2023 | $8,880,629 | -13.8% | 238,855 | +5.1% | 0.01% | -16.7% |
| Q4 2022 | $10,299,915 | -27.2% | 227,321 | +12.2% | 0.01% | -33.3% |
| Q3 2022 | $14,152,000 | -9.4% | 202,633 | -12.9% | 0.01% | 0.0% |
| Q2 2022 | $15,626,000 | -14.9% | 232,752 | +4.2% | 0.01% | 0.0% |
| Q1 2022 | $18,361,000 | -42.9% | 223,323 | +1.8% | 0.01% | -35.7% |
| Q4 2021 | $32,175,000 | -67.5% | 219,340 | -60.8% | 0.01% | -70.2% |
| Q3 2021 | $99,014,000 | +9.3% | 559,688 | -0.2% | 0.05% | +6.8% |
| Q2 2021 | $90,623,000 | +132.8% | 561,032 | +146.9% | 0.04% | +109.5% |
| Q1 2021 | $38,931,000 | -31.5% | 227,267 | -12.1% | 0.02% | -40.0% |
| Q4 2020 | $56,809,000 | +178.1% | 258,648 | +110.3% | 0.04% | +150.0% |
| Q3 2020 | $20,425,000 | +9.7% | 123,006 | -24.6% | 0.01% | 0.0% |
| Q2 2020 | $18,623,000 | +5.0% | 163,118 | -29.3% | 0.01% | -12.5% |
| Q1 2020 | $17,733,000 | -43.9% | 230,687 | -6.0% | 0.02% | -23.8% |
| Q4 2019 | $31,615,000 | +381.9% | 245,363 | +191.3% | 0.02% | +320.0% |
| Q3 2019 | $6,560,000 | -80.2% | 84,236 | -73.9% | 0.01% | -73.7% |
| Q2 2019 | $33,186,000 | +531.0% | 322,207 | +349.0% | 0.02% | +533.3% |
| Q1 2019 | $5,259,000 | +39.2% | 71,765 | -19.4% | 0.00% | 0.0% |
| Q4 2018 | $3,777,000 | -80.7% | 89,073 | -78.6% | 0.00% | -50.0% |
| Q3 2018 | $19,559,000 | +94.5% | 415,306 | +103.6% | 0.01% | +100.0% |
| Q2 2018 | $10,056,000 | +134.5% | 204,020 | +46.0% | 0.00% | +50.0% |
| Q1 2018 | $4,289,000 | +14196.7% | 139,770 | +8335.1% | 0.00% | – |
| Q4 2017 | $30,000 | -84.5% | 1,657 | -90.0% | 0.00% | – |
| Q3 2017 | $193,000 | +221.7% | 16,545 | 0.0% | 0.00% | – |
| Q2 2017 | $60,000 | -76.9% | 16,545 | -67.1% | 0.00% | – |
| Q1 2017 | $260,000 | +67.7% | 50,324 | +53.3% | 0.00% | – |
| Q4 2016 | $155,000 | -80.3% | 32,836 | -72.5% | 0.00% | -100.0% |
| Q3 2016 | $787,000 | -49.3% | 119,232 | -58.1% | 0.00% | 0.0% |
| Q2 2016 | $1,552,000 | -60.6% | 284,518 | +54.4% | 0.00% | -66.7% |
| Q1 2016 | $3,942,000 | -32.7% | 184,242 | -0.6% | 0.00% | -25.0% |
| Q4 2015 | $5,856,000 | -8.5% | 185,347 | -0.4% | 0.00% | -20.0% |
| Q3 2015 | $6,401,000 | +4083.7% | 186,018 | +3701.7% | 0.01% | – |
| Q2 2015 | $153,000 | -81.0% | 4,893 | -82.2% | 0.00% | -100.0% |
| Q1 2015 | $806,000 | +116.7% | 27,533 | +37.0% | 0.00% | – |
| Q4 2014 | $372,000 | +5.4% | 20,104 | -0.3% | 0.00% | – |
| Q3 2014 | $353,000 | -13.1% | 20,171 | -0.8% | 0.00% | – |
| Q2 2014 | $406,000 | 0.0% | 20,335 | -4.9% | 0.00% | – |
| Q1 2014 | $406,000 | +18.7% | 21,378 | +3.7% | 0.00% | – |
| Q4 2013 | $342,000 | -20.8% | 20,606 | -28.0% | 0.00% | – |
| Q3 2013 | $432,000 | – | 28,627 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $136,602,679 | 87.83% |
| EcoR1 Capital, LLC | 5,748,399 | $250,400,260 | 8.45% |
| Boxer Capital, LLC | 3,201,440 | $139,454,726 | 7.42% |
| RTW INVESTMENTS, LP | 6,768,514 | $294,836,470 | 6.22% |
| Paradigm Biocapital Advisors LP | 1,668,116 | $72,663,133 | 4.93% |
| Avoro Capital Advisors LLC | 6,666,666 | $290,399,971 | 4.53% |
| Octagon Capital Advisors LP | 655,051 | $28,534,022 | 4.38% |
| Artal Group S.A. | 2,024,226 | $88,175 | 3.78% |
| Ally Bridge Group (NY) LLC | 70,283 | $3,061,527 | 3.59% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 216,000 | $9,404,640 | 3.17% |